The Union Health Ministry has approved the fixed-dose combination (FDC) of Tamsulosin HCI and Deflazacort for asthma therapy through a gazetted notification.
The notification said that the fixed-dose combination of Tamsulosin HCI 0.4 mg and Deflazacort 30mg in hard gelatine capsule will be withdrawn from the list of medicines that are banned for manufacture and sale.
In recent years, diet and lifestyle have been recognized as crucial factors influencing cancer risk.…
Surgical advancements have evolved significantly over the decades, leading to improved precision, reduced recovery time,…
A tragic incident in northwest Delhi has sparked a medical negligence controversy after a 20-year-old…
Maharashtra is set to witness a significant transformation in its public health sector with the…
Sleep is essential for overall health, yet many people suffer from sleep disorders that disrupt…
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…